Beacon Biosignals announced on October 22, 2026, that it has acquired Snap Diagnostics, a home sleep testing provider serving patients in all 50 states. The deal more than doubles Beacon's patient reach and establishes the company as one of the largest home sleep testing providers in the United States. The acquisition also creates a national channel to introduce EEG-enabled home sleep testing to more patients beginning in 2027.
Why the Acquisition Matters
Snap Diagnostics operates an end-to-end service that lets primary care physicians, advanced practice providers, telehealth providers, and specialists order home sleep tests without in-house sleep expertise. The company ships tests directly to patients, scores every study, and coordinates interpretation by qualified sleep professionals according to American Academy of Sleep Medicine guidance. As a Medicare-registered Independent Diagnostic Testing Facility, Snap also bills Medicare and commercial insurers directly, removing administrative burdens from clinicians.
EEG Technology Expands Diagnostic Insight
Consumer wearables and cardiopulmonary devices estimate sleep indirectly from movement, heart rate, and airflow, but Beacon's FDA 510(k)-cleared Waveband headband measures electrical brain activity directly. This EEG signal captures the sleep fragmentation behind many daytime symptoms and long-term risks of obstructive sleep apnea. Combined with AI-driven analysis from the Beacon Platform, EEG-enabled home testing gives clinicians a more complete picture of disturbed nighttime sleep without requiring an overnight lab visit.
Continuity for Snap Customers
For the foreseeable future, Snap will remain a subsidiary of Beacon Biosignals with no change to its name or services. Existing patients and ordering clinicians can continue to use Snap's established process for home sleep testing, scoring, interpretation, and billing. Beacon expects the integration to expand patient access, improve provider efficiency, and avoid disruption to current clinical workflows.
Addressing a National Gap in Sleep Care
Nearly one in three Americans experience sleep symptoms, yet there are only about 6,000 board-certified sleep physicians in the country. Home sleep apnea testing is appropriate for uncomplicated adult patients whose signs and symptoms indicate an increased risk of moderate to severe obstructive sleep apnea. By making sleep testing more accessible through primary care and other specialties, Beacon aims to identify more patients who need evaluation and connect them with the right care.
Broader Brain Health Ambitions
Beacon's technology already supports clinical trials across neurological, psychiatric, and sleep disorders with more than half of the world's top 10 biopharmaceutical companies. These partners rely on clinically validated EEG and AI-derived biomarkers from the Beacon Platform to evaluate the next generation of brain health therapies. The acquisition creates a pathway to bring the same neurophysiology and AI capabilities into broader clinical care and bridge drug development with patient care.
The acquisition positions Beacon Biosignals to expand access to clinical-grade home sleep testing across the United States while preparing for the introduction of EEG-enabled testing in 2027. It strengthens the company's ability to serve both sleep specialists and the broader medical community without requiring in-house sleep expertise. Over time, Beacon sees at-home neurophysiology as a tool that could help identify early signs of neurodegenerative disease and support more personalized psychiatric care.